Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays
Azole antifungals, designed to inhibit fungal CYP51, have a liability to inhibit human CYP enzymes. Whilst drug-metabolizing CYPs are covered in preclinical safety assessment, those metabolizing endogenous bioactive molecules are usually not. Posaconazole and itraconazole were recently found to caus...
Main Authors: | Marie-Christin Jäger, Friedrich L. Joos, Denise V. Winter, Alex Odermatt |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Current Research in Toxicology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666027X23000178 |
Similar Items
-
Potential role of broad-spectrum azoles as therapy for Malasezzia bloodstream infection
by: Sunish Shah, et al.
Published: (2023-09-01) -
Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole
by: Paulien E. Bunskoek, et al.
Published: (2017-06-01) -
INK128 exhibits synergy with azoles against Exophiala spp. and Fusarium spp.
by: Lujuan Gao, et al.
Published: (2016-10-01) -
New Antifungal Agents with Azole Moieties
by: Melissa Martins Teixeira, et al.
Published: (2022-11-01) -
Conazoles
by: Jan Heeres, et al.
Published: (2010-06-01)